Clinical evaluation of belimumab combined with hydroxychloroquine sulfate in the treatment of lupus nephritis
ZHENG Lili
FENG Yuan
ZHAO Cuifen
CHAO Shaorong
LI Yuying
CAO Xue
Abstract：Objective To explore the efficacy and safety of belimumab combined with hydroxychloroquine sulfate in the treatment of lupus nephritis(LN).Methods A total of 104 LN patients who received targeted treatment at the Second Affiliated Hospital of the Air Force Military Medical University from May 2021 to December 2024 were selected as subjects for this trial and randomly allocated into two groups:the control group(52 patients)received hydroxychloroquine sulfate treatment,and the observation group(52 patients)received belimumab combined with hydroxychloroquine sulfate treatment.The clinical efficacy,renal function indicators(serum creatinine(Scr),blood urea nitrogen(BUN),24-hour urinary protein quantification(24 h-UPro)),erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),immune function indicators(complement(C3,C4),immunoglobulins(IgA,IgG,IgM))levels,and the incidence of adverse reactions were compared be-tween the two groups before and after treatment.Results The total effective rate in observation group was 92.31%(48/52),higher than that in the control group(78.85%,41/52)(χ2=5.279,P＜0.05).After treatment,both groups showed decreased Scr,BUN,and 24 h-UPro levels compared to pre-treatment levels,and the levels in the observation group((95.48±14.66)µmol/L,(7.16±1.22)mmol/L,(0.41±0.09)mg/24 h,respectively)were lower than those in the control group((124.65±15.42)µmol/L,(9.27±1.33)mmol/L,(0.68±0.12)mg/24 h,respectively)(t=9.886,8.431,12.980,all P＜0.05).After treatment,ESR and CRP levels decreased in both groups,with the observation group exhibiting lower levels((21.88±6.01)mm/h,(4.03±1.85)mg/L)than the control group((35.49±5.82)mm/h,(6.57±1.51)mg/L)(t=4.446,7.670,both P＜0.05).After treatment,C3 and C4 levels increased in both groups,and the levels in the observation group((1.22±0.30)g/L,(0.33±0.10)g/L)were higher than those in the control group((0.87±0.25)g/L,(0.24±0.07)g/L)(t=8.286,3.379,both P＜0.05).After treatment,IgG,IgM,and IgA levels decreased in both groups,with the observation group showing lower values((12.85±1.64)g/L,(1.71±0.22)g/L,(2.27±0.39)g/L)than the control group((17.87±1.51)g/L,(2.16±0.31)g/L,(2.91±0.47)g/L)(t=16.238,8.537,7.557,all P＜0.05).The incidence of adverse reactions was 7.69%(4/52)in the observation group and 19.23%(10/52)in the control group,with no statistically significant difference between the two groups(χ2=2.971,P＞0.05).Conclusion The combination therapy of belimumab and hydroxychloroquine sulfate in the treatment of LN demonstrates significant efficacy,effectively improving patients'inflammatory status,correcting immune dysfunction,protecting renal function,and demonstrating good safety.
Keywords：lupus nephritissystemic lupus erythematosusclinical efficacybelimumabhydroxychloroquine sulfate
Publication Date：2025-12-25
Online Publishing Date：2026-01-07(First online date of this platform, not the publication date of the document)
Pages：5( 1517-1521 )